Rahmawati, Siti Farah
Vos, RĂ©mon
Bos, I. Sophie T.
Kerstjens, Huib A. M.
Kistemaker, Loes E. M.
Gosens, Reinoud
Funding for this research was provided by:
lembaga pengelola dana pendidikan (LPDP) Indonesia
Sanofi-Genzyme
Article History
Received: 8 March 2022
Accepted: 23 June 2022
First Online: 30 June 2022
Competing interests
: SFR received a scholarship from lembaga pengelola dana pendidikan (LPDP) Indonesia. SFR and RG received research funding, to the institution, from Sanofi-Genzyme for the development of novel drugs targeting the IL-17 pathway. In addition, RG received research funding from Aquilo and Boehringer Ingelheim, to the institution, outside the scope of the present study. STB declares no competing interest. RV declares no competing interest. LK is an employee of Aquilo BV. HK reports no competing interests in relation to the topic of this manuscript. His institution has received funding from Boehringer for investigator-initiated studies as well as for consultancies, all outside the scope of the work presented here.